MDGL research · 13F holders by reporting quarter
Madrigal Pharmaceuticals, Inc. (MDGL): 13F holders, 2025Q3
The largest share positions in MDGL that the managers Kresmion follows reported on Form 13F for 2025Q3, as filed. The current quarter, the company's SEC filings and its recent events are on the MDGL research page.
MDGL positions held by the managers we follow (2025Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 558868105 · 2025Q3 | $55.4M | 0.07% |
| D. E. Shaw & Co., Inc. FundCUSIP 558868105 · 2025Q3 | $44.1M | 0.04% |
| CITADEL ADVISORS LLC FundCUSIP 558868105 · 2025Q3 | $22.2M | 0.02% |
| Point72 Asset Management, L.P. FundCUSIP 558868105 · 2025Q3 | $18.9M | 0.04% |
| Bridgewater Associates, LP FundCUSIP 558868105 · 2025Q3 | $12.7M | 0.05% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 558868105 · 2025Q3 | $825K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.